Cargando…
LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Parkinson’s Disease (PD) affects millions of people worldwide with no cure to halt the progress of the disease. Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of PD and, as such, LRRK2 inhibitors are promising therapeutic agents. In the last decade, great progress in the LRRK2...
Autores principales: | Wojewska, Dominika Natalia, Kortholt, Arjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392603/ https://www.ncbi.nlm.nih.gov/pubmed/34439767 http://dx.doi.org/10.3390/biom11081101 |
Ejemplares similares
-
Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease
por: Rosenbusch, Katharina E., et al.
Publicado: (2016) -
LRRK2 Structure-Based Activation Mechanism and Pathogenesis
por: Zhang, Xiaojuan, et al.
Publicado: (2023) -
Allosteric inhibition of LRRK2, where are we now
por: Soliman, Ahmed, et al.
Publicado: (2020) -
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation
por: Gilsbach, Bernd K., et al.
Publicado: (2014) -
Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
por: Rideout, Hardy, et al.
Publicado: (2022)